
    
      The study is a prospective, randomized, parallel group, double-blind, placebo-controlled
      phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with
      add-back therapy for the treatment of uterine fibroids.

      Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.
    
  